{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T23:22:39Z","timestamp":1787440959283,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biopha.2026.119544","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:12:29Z","timestamp":1779307949000},"page":"119544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Insulin plant (Costus igneus) extract alleviates steatosis and adiposity in a murine MASLD model by modulating hepatic lipogenesis and the CD9-CFD immunoregulatory axis"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7750-4405","authenticated-orcid":false,"given":"Nikhil Y.","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0881-4036","authenticated-orcid":false,"given":"Rosario","family":"Mare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8149-7957","authenticated-orcid":false,"given":"Francesca","family":"Scionti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateswararao","family":"Eeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5208-5144","authenticated-orcid":false,"given":"Aditya D.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-9009","authenticated-orcid":false,"given":"Vibhudutta","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2026.119544_bib1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"Younossi","year":"2020","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.biopha.2026.119544_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"26","key":"10.1016\/j.biopha.2026.119544_bib3","doi-asserted-by":"crossref","first-page":"8341","DOI":"10.3748\/wjg.v20.i26.8341","article-title":"Modern approach to the clinical management of non-alcoholic fatty liver disease","volume":"20","author":"Del Ben","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119544_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2026.119544_bib5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2006.02.004","article-title":"A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease","volume":"4","author":"Zelber-Sagi","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119544_bib6","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/hep4.1993","article-title":"Combination of tofogliflozin and pioglitazone for NAFLD: extension to the ToPiND randomized controlled trial","volume":"6","author":"Yoneda","year":"2022","journal-title":"Hepatol. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2026.119544_bib7","first-page":"2005","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases","volume":"55","author":"Chalasani","year":"2012","journal-title":"Am. Coll. Gastroenterol. Am. Gastroenterol. Assoc. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119544_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"issue":"11","key":"10.1016\/j.biopha.2026.119544_bib9","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119544_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis","author":"Noureddin","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1 Suppl","key":"10.1016\/j.biopha.2026.119544_bib11","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119544_bib12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jhep.2005.08.002","article-title":"Herbal hepatotoxicity","volume":"43","author":"Stickel","year":"2005","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119544_bib13","doi-asserted-by":"crossref","first-page":"7386","DOI":"10.3168\/jds.2014-8500","article-title":"Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease","volume":"97","author":"Nabavi","year":"2014","journal-title":"J. Dairy Sci."},{"issue":"6","key":"10.1016\/j.biopha.2026.119544_bib14","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/07315724.2015.1031355","article-title":"Moayed, effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial","volume":"35","author":"Sepideh","year":"2016","journal-title":"J. Am. Coll. Nutr."},{"issue":"1","key":"10.1016\/j.biopha.2026.119544_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial","volume":"27","author":"Kobyliak","year":"2018","journal-title":"J. Gastrointestin Liver Dis."},{"issue":"1","key":"10.1016\/j.biopha.2026.119544_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2019-000315","article-title":"High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study","volume":"6","author":"Duseja","year":"2019","journal-title":"BMJ Open Gastroenterol."},{"key":"10.1016\/j.biopha.2026.119544_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108294","article-title":"Comparative efficacy of different treatment modalities in the management of pediatric non-alcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"240","author":"Theodoridis","year":"2022","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2026.119544_bib18","article-title":"Possible hepatoprotective effect of tocotrienol-rich fraction Vitamin E in non-alcoholic fatty liver disease in obese children and adolescents","volume":"9","author":"Al-Baiaty","year":"2021","journal-title":"Front. Pedia."},{"issue":"18","key":"10.1016\/j.biopha.2026.119544_bib19","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, Vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2026.119544_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ajcn\/nqac260","article-title":"Association between serum 25-hydroxy vitamin D concentrations and mortality among individuals with metabolic dysfunction-associated fatty liver disease: a prospective cohort study","author":"Zhang","year":"2022","journal-title":"Am. J. Clin. Nutr."},{"issue":"6","key":"10.1016\/j.biopha.2026.119544_bib21","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/hep.25930","article-title":"Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus","volume":"56","author":"Barchetta","year":"2012","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.biopha.2026.119544_bib22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00431-021-04243-4","article-title":"Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial","volume":"181","author":"Amrousy","year":"2022","journal-title":"Eur. J. Pedia"},{"issue":"12","key":"10.1016\/j.biopha.2026.119544_bib23","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s42255-022-00700-y","article-title":"A researcher's guide to preclinical mouse NASH models","volume":"4","author":"Gallage","year":"2022","journal-title":"Nat. Metab."},{"issue":"29","key":"10.1016\/j.biopha.2026.119544_bib24","article-title":"CD9 counteracts liver steatosis and mediates GCGR agonist hepatic effects","volume":"11","author":"Zheng","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"6","key":"10.1016\/j.biopha.2026.119544_bib25","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cgh.2023.11.003","article-title":"Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020","volume":"22","author":"Kalligeros","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119544_bib26","article-title":"Plant-based foods and their bioactive compounds on fatty liver disease: effects, mechanisms, and clinical application","volume":"2021","author":"Li","year":"2021","journal-title":"Oxid. Med. Cell Longev."},{"issue":"11","key":"10.1016\/j.biopha.2026.119544_bib27","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1542-3565(04)00455-0","article-title":"Use of herbal supplements for chronic liver disease","volume":"2","author":"Levy","year":"2004","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119544_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00204-015-1580-z","article-title":"A comprehensive overview of hepatoprotective natural compounds: mechanism of action and clinical perspectives","volume":"90","author":"Domitrovic","year":"2016","journal-title":"Arch. Toxicol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119544_bib29","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/aps.2012.62","article-title":"Differential hepatoprotective mechanisms of rutin and quercetin in CCl(4)-intoxicated BALB\/cN mice","volume":"33","author":"Domitrovic","year":"2012","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.biopha.2026.119544_bib30","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1039\/c3fo60526d","article-title":"The high antioxidative power of quercetin (aglycone flavonoid) and its glycone (rutin) avert high cholesterol diet induced hepatotoxicity and inflammation in Swiss albino mice","volume":"5","author":"Sikder","year":"2014","journal-title":"Food Funct."},{"issue":"1","key":"10.1016\/j.biopha.2026.119544_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1248\/jhs.57.37","article-title":"The efficacy of costus igneus rhizome on carbohydrate metabolic, hepatoproductive and antioxidative enzymes in streptozotocin-induced diabetic rats","volume":"57","author":"Kalailingam","year":"2011","journal-title":"J. Health Sci."},{"key":"10.1016\/j.biopha.2026.119544_bib32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.imu.2018.10.004","article-title":"Chromatographic analysis of phytochemicals in Costus igneus and computational studies of flavonoids","volume":"13","author":"Peasari","year":"2018","journal-title":"Inform. Med. Unlocked"},{"key":"10.1016\/j.biopha.2026.119544_bib33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.fct.2018.07.036","article-title":"Potential synergistic effects of quercetin with other phytoconstituents of Costus pictus (insulin plant) extract in the control of hyperglycemia and prevention of NSAID-induced gastroenteropathy in diabetic rats","volume":"120","author":"Borse","year":"2018","journal-title":"Food Chem. Toxicol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119544_bib34","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1210\/en.2014-2003","article-title":"Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21","volume":"156","author":"Assini","year":"2015","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119544_bib35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11095-005-9043-5","article-title":"Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells","volume":"23","author":"Liu","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2026.119544_bib36","article-title":"Apigenin alleviates liver fibrosis by inhibiting hepatic stellate cell activation and autophagy via TGF-beta1\/Smad3 and p38\/PPARalpha pathways","author":"Ji","year":"2021","journal-title":"PPAR Res 2021"},{"key":"10.1016\/j.biopha.2026.119544_bib37","first-page":"9139","article-title":"Apigenin suppresses MED28-mediated cell growth in human liver cancer cells","author":"Chou","year":"2024","journal-title":"J. Agric. Food Chem. 72(16"},{"key":"10.1016\/j.biopha.2026.119544_bib38","first-page":"2965","article-title":"Apigenin reduces the excessive accumulation of lipids induced by palmitic acid via the AMPK signaling pathway in HepG2 cells","author":"Lu","year":"2019","journal-title":"Exp. Ther. Med. 18(4)"},{"issue":"4","key":"10.1016\/j.biopha.2026.119544_bib39","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1055\/s-0028-1091980","article-title":"Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease","volume":"28","author":"Malhi","year":"2008","journal-title":"Semin Liver Dis."},{"issue":"2","key":"10.1016\/j.biopha.2026.119544_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2023.113655","article-title":"Oleic acid improves hepatic lipotoxicity injury by alleviating autophagy dysfunction","volume":"429","author":"Liu","year":"2023","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.biopha.2026.119544_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12986-020-0434-8","article-title":"Oleic acid ameliorates palmitic acid induced hepatocellular lipotoxicity by inhibition of ER stress and pyroptosis","volume":"17","author":"Zeng","year":"2020","journal-title":"Nutr. Metab. (Lond.)"},{"issue":"3","key":"10.1016\/j.biopha.2026.119544_bib42","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2022.5169","article-title":"Role of Ca(2+) channels in non-alcoholic fatty liver disease and their implications for therapeutic strategies (Review)","volume":"50","author":"Chen","year":"2022","journal-title":"Int. J. Mol. Med."},{"issue":"45","key":"10.1016\/j.biopha.2026.119544_bib43","doi-asserted-by":"crossref","first-page":"11926","DOI":"10.1073\/pnas.1706489114","article-title":"Increased intracellular Ca(2+) concentrations prevent membrane localization of PH domains through the formation of Ca(2+)-phosphoinositides","volume":"114","author":"Kang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2026.119544_bib44","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1038\/ncomms5834","article-title":"Pharmacological correction of obesity-induced autophagy arrest using calcium channel blockers","volume":"5","author":"Park","year":"2014","journal-title":"Nat. Commun."},{"issue":"4911","key":"10.1016\/j.biopha.2026.119544_bib45","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1126\/science.2734615","article-title":"Adipsin and complement factor D activity: an immune-related defect in obesity","volume":"244","author":"Rosen","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119544_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.712572","article-title":"Complement factor D as a strategic target for regulating the alternative complement pathway","volume":"12","author":"Barratt","year":"2021","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119544_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.molimm.2014.10.017","article-title":"Alternative complement pathway component Factor D contributes to efficient clearance of tissue debris following acute CCl(4)-induced injury","volume":"64","author":"Cresci","year":"2015","journal-title":"Mol. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119544_bib48","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat. Metab."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226005809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226005809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:59:21Z","timestamp":1787439561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226005809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"alternative-id":["S0753332226005809"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119544","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insulin plant (Costus igneus) extract alleviates steatosis and adiposity in a murine MASLD model by modulating hepatic lipogenesis and the CD9-CFD immunoregulatory axis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119544"}}